Juno Therapeutics is now the “cheapest” player now developing CAR-T cancer medications, an analyst said Wednesday as he downgraded rival Bluebird Bio.
Juno Therapeutics is now the “cheapest” player now developing CAR-T cancer medications, an analyst said Wednesday as he downgraded rival bluebird bio.
Both are working on CAR-T therapies in which a patient’s immune cells are extracted, taught to fight cancer and then reintroduced to the body. Juno and Bluebird each had strong data during the American Society of Hematology conference in Atlanta.
